ImageneBio, Inc.

IMA Healthcare Biotechnology

ImageneBio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $800,000.00, down 77.1% from fiscal 2024. In the quarter to June 2026, revenue fell 60.1%, EPS grew 12.5% and free cash flow grew 23.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

4.04 0.01 +0.25%
Market cap
$45.7M
P/E
0.0×
Fwd P/E
−1.3×
Dividend yield
—
F-score
3/9
Altman Z
−1.12
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

(42.19%) 225.87% (44.61%) (41.34%)
ROA
(37.32%) (62.04%) (40.29%) (38.34%)
ROIC
0.00% 0.00% (557.03%) (622.37%)
Return on Tangible Assets
(42.39%) (40.60%) (46.71%) (39.64%)
Average Days of Receivables
— — — —
Free Cash Flow per Share
(5.17) (9.82) (4.94) (3.25)
Free Cash Flow
(44.10) (47.84) (55.41) (52.59)
Other line items

Show all line items

Columns are period end dates